Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era

  • Future Drug Discov. 2022 Apr;4(1):FDD73. doi: 10.4155/fdd-2022-0001.
Colin J Suckling  1 ,  Iain S Hunter  2 ,  Fraser J Scott  1
Affiliations
  • 1. Department of Pure & Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL, UK.
  • 2. Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
PMID: 35600289 DOI: 10.4155/fdd-2022-0001
Abstract

The standard drug discovery paradigm of single molecule - single biological target - single biological effect is perhaps particularly unsuitable for anti-infective drug discovery. This is due to the rapid evolution of resistance likely to be observed with single target drugs. Multitargeted anti-infective drugs are likely to be superior due to their lower susceptibility to target-related resistance mechanisms. Strathclyde minor groove Binders are a class of compounds which have been developed by adopting the multitargeted anti-infective drugs paradigm, and their effectiveness against a wide range of pathogenic organisms is discussed. The renaming of this class to Strathclyde nucleic acid Binders is also presented due to their likely targets including both DNA and RNA.

Keywords
DNA; RNA; Strathclyde minor groove binders; anti-infectives; antimicrobial resistance; multitargeting anti-infective drugs; nucleic acids; strathclyde nucleic acid binders.
Products